We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CHOICE: Carotid Stenting For High Surgical-Risk Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00406055
First Posted: December 4, 2006
Last Update Posted: July 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Abbott Vascular
November 29, 2006
December 4, 2006
July 26, 2013
October 2006
June 2012   (Final data collection date for primary outcome measure)
Composite of death, stroke, and MI (DSMI) [ Time Frame: 30 days ]
Composite of death, stroke, and MI (DSMI) at 30 days.
Complete list of historical versions of study NCT00406055 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
CHOICE: Carotid Stenting For High Surgical-Risk Patients
Carotid Stenting For High Surgical-Risk Patients; Evaluating Outcomes Through The Collection Of Clinical Evidence
The purposes of this study is to 1) Provide additional information that the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems can be used successfully by a wide range of physicians under commercial use conditions. 2) Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
The CHOICE study will provide a mechanism for collection of data from Abbott Vascular's Carotid Stent Systems and Embolic Protection Systems when used by a broad group of physicians under commercial use conditions. The original CAPTURE and EXACT studies had built-in features that limited the ability to collect on-going real world data because they restricted the number of sites that could participate (up to 150 sites) and limited enrollment at each site (up to 50 patients per site). This study will not have these restrictions. The CHOICE study will also provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients enrolled into this registry will be male and female patients derived from the general population who satisfy the inclusion and exclusion criteria.
Carotid Artery Disease
Device: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
1
Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
Intervention: Device: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18855
June 2012
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient or patient's legally authorized representative provided informed consent.
  2. Patient is considered at high risk for carotid endarterectomy (CEA).
  3. Patient requires percutaneous carotid angioplasty and stenting for carotid artery disease.
  4. Patients physician intends to use an RX Acculink with either the RX Accunet or Emboshield Nav 6 in the carotid artery OR the patients physician intends to use an Xact with the Emboshield or Emboshield Nav6 in the carotid artery as per the FDA approved Indications for Use as outlined.

Exclusion Criteria:

There are no exclusion criteria for this study

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00406055
06-717
Not Provided
Not Provided
Not Provided
Abbott Vascular
Abbott Vascular
Not Provided
Study Chair: William Gray, M.D.
Abbott Vascular
July 2013